secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0000950170-25-042342
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics appoints Abizer Gaslightwala President and CEO; Samir Patel steps down effective April 14, 2025
--------------------------------------------------------------------------------

- Abizer Gaslightwala appointed President and CEO effective ~April 21, 2025; prior SVP at Jazz Pharmaceuticals.
- Annual base salary $475,000, target cash bonus of 50% base; time-based option for 1,100,000 ADS (4-yr vest).
- Performance-based option for 600,000 ADS vests upon: ≥$15M financing or ≥$10M upfront ADC license by Dec 31, 2025.
- Samir Patel steps down as CEO effective April 14, 2025, remains on Board; separation terms pending.
- New CEO's employment includes non-compete on ADC-focused biopharma for 12 months post-employment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017025042342/0000950170-25-042342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017025042342/aktx-20250314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-042342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer